Journal of Artificial Organs

, Volume 22, Issue 2, pp 177–180 | Cite as

Re-do mitral valve replacement for a bioprosthetic valve with central transvalvular leakage in a patient with ischemic cardiomyopathy: a case report

  • Tatsuya Seki
  • Yasushige ShinguEmail author
  • Satoru Wakasa
  • Hiroki Katoh
  • Tomonori Ooka
  • Tsuyoshi Tachibana
  • Suguru Kubota
  • Yoshiro Matsui
Case Report Artificial Valve


Transvalvular leakage (TVL) of a prosthetic heart valve is not negligible regurgitant flow in patients with critically low contractile function. Although the opening function of prosthetic valves has been reported, its closing function is not well understood. A man in his 70 s had a history of mitral valve replacement (MVR) with a Magna Mitral® valve for ischemic mitral valve regurgitation. He presented with dyspnea 2 years postoperatively. Echocardiography showed moderate TVL. The pulmonary capillary wedge pressure and cardiac index were 37 mmHg and 1.65 L/min/m2, respectively. Because we considered his TVL relevant, we performed re-do MVR with a mechanical valve and papillary muscle approximation and suspension (“papillary muscle tugging approximation”). His cardiac function improved postoperatively; he was discharged with New York Heart Association class I. For MVR in patients with critically low contractile function, prosthetic valves, such as mechanical valves, with small TVL are recommended.


Bioprosthetic valve Mechanical valve Transvalvular leakage 



We would like to thank Editage ( for English language editing.

Compliance with ethical standards

Conflict of interest

The authors have no conflicts of interest to declare.


  1. 1.
    Baumgartner H, Falk V, Bax JJ, et al. ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017;38:2739–86.CrossRefGoogle Scholar
  2. 2.
    Nishimura RA, Otto CM, Bonow RO, et al. AHA/ACC focused update of the AHA/ACC guideline for the management of patients with valvular heart disease. Circulation 2017;135:1159–95.CrossRefGoogle Scholar
  3. 3.
    Banbury MK, Cosgrove DM, White JA, et al. Age and valve size effect on the long-term durability of the Carpentier-Edwards aortic pericardial bioprosthesis. Ann Thorac Surg 2001;72:753–7.CrossRefGoogle Scholar
  4. 4.
    Kuehnel R, Puchner R, Pohl A, et al. Characteristic resistance curves of aortic valve substitutes facilitate individualized decision for a particular type. Eur J Cardiothorac Surg 2005;27:450–5.CrossRefGoogle Scholar
  5. 5.
    Dalmau MJ, Gonzalez-Santos JM, Lopez-Rodrguez MB, et al. The Carpentier-Edwards Perimount Magna aortic xenograft: a new design with an improved hemodynamic performance. Interact Cardiocasc Thorac Surg 2006;5:263–7.CrossRefGoogle Scholar
  6. 6.
    Matsui Y, Shingu Y, Wakasa S, Ooka T, Kubota S Papillary muscle tugging approximation for functional mitral regurgitation. Ann Thorac Surg;2018 (in press)Google Scholar
  7. 7.
    Gerosa G, Tarzia V, Rizzoli G, et al. Small aortic annulus: the hydrodynamic performances of 5 commercially available tissue valves. J Thorac Cardiovasc Surg. 2006;131:1058–64.CrossRefGoogle Scholar
  8. 8.
    Dzemali O, Bakhtiary F, Steinseiffer U, et al. Hemodynamic performance of fresh and calcified aortic valve prostheses in critical low stroke volume. J Heart Valv Dis. 2008;17:317–24.Google Scholar
  9. 9.
    Bottio T, Caprili L, Casarotto D, et al. Small aortic annulus: The hydrodynamic performances of 5 commercially available bileaflet mechanical valves. J Thorac Cardiovasc Surg. 2004;128:457–62.CrossRefGoogle Scholar
  10. 10.
    Fino C, Iacovoni A, Pibarot P, et al. Exercise hemodynamic and functional capacity after mitral valve replacement in patients with ischemic mitral regurgitation. Circ Hear Fail. 2018;11:e004056. Scholar
  11. 11.
    Acker MA, Adams DH, Ailawadi G, et al. 2016 update to The American Association for Thoracic Surgery consensus guidelines: Ischemic mitral valve regurgitation. J Thorac Cardiovasc Surg. 2017;153:1076–9.CrossRefGoogle Scholar
  12. 12.
    David TE, Burns RJ, Bacchus CM. Mirel valve replacement for mitral regurgitation with and without preservation of chordae tendineae. J Thorac Cardiovasc Surg. 1984;88:718–25.Google Scholar
  13. 13.
    Yun KL, Sintek CF, Miller DC, et al. Randomized trial of partial versus complete chordal preservation methods of mitral valve replacement. A Prelimin Rep Circ. 1999;100:90–4.Google Scholar
  14. 14.
    Goldstein D, Moskowitz AJ, Gelijns AC, et al. Two-year outcomes of surgical treatment of severe ischemic mitral regurgitation. N Engl J Med. 2016;374:344–53.CrossRefGoogle Scholar

Copyright information

© The Japanese Society for Artificial Organs 2019

Authors and Affiliations

  • Tatsuya Seki
    • 1
  • Yasushige Shingu
    • 1
    Email author
  • Satoru Wakasa
    • 1
  • Hiroki Katoh
    • 2
  • Tomonori Ooka
    • 1
  • Tsuyoshi Tachibana
    • 1
  • Suguru Kubota
    • 1
  • Yoshiro Matsui
    • 1
  1. 1.Department of Cardiovascular and Thoracic Surgery, Faculty of Medicine, Graduate School of MedicineHokkaido UniversitySapporoJapan
  2. 2.Emergency and Critical Care CenterHokkaido University HospitalSapporoJapan

Personalised recommendations